Oriola and MSD signed distribution agreement for Swedish market

Oriola Corporation Investor news 1 October 2019 at 2.00 p.m.

Oriola and MSD signed distribution agreement for Swedish market

Oriola and pharmaceutical company MSD have signed a new distribution agreement for the Swedish market. According to the new agreement, Oriola provides MSD with pharmaceutical storage and distribution services for human medicines. The new agreement is valid from 1 October 2019.

MSD is a global pharmaceutical company innovating within many therapeutic areas such as oncology, vaccines, infectious diseases as well as animal health products. The wholesales value of MSD's human pharmaceuticals was in Sweden approximately 210 million euro in 2018 and market share of the Swedish pharmaceutical market approximately 4.8% in 2018 (source: Reveal).

“Our strategic goal in Oriola is to be a reliable partner for our customers in the pharmaceutical industry. The demanding and strongly regulated pharmaceutical logistics is at the core of our competence. I’m happy to start this cooperation with MSD, one of the biggest pharmaceutical companies in our market. Our common goal is to secure fluent medical flow for customers,” tells Thomas Gawell, VP, Business Area Pharma.

Oriola is responsible for more than a 40% of pharmaceutical distribution in Sweden. It delivers pharmaceuticals for pharmacies, hospitals as well as other healthcare operators all over Sweden. Additionally, Oriola sells and markets health and wellbeing products as well as veterinary pharmaceuticals and products for pharmacies, veterinaries and other retail operators.

Further information:

Tuula Lehto
Group Communications Director
Tel. +358 40 5885 343
Email: tuula.lehto@oriola.com